CD99 and Ewing sarcoma: Should anti-CD99 therapeutics gain further traction for study in patients with Ewing sarcoma, important considerations for on-target, off-tumor toxicity will be relevant given the expression of CD99 on other human tissues, most notably leukocytes and pancreatic beta-islet cells [41,42] (https://www.proteinatlas.org).